← Back to Clinical Trials
Recruiting NCT07211321

NCT07211321 Linking Diet, Inflammation, Gut Microbiota, and Sarcopenia: A Cross-Sectional Study

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07211321
Status Recruiting
Phase
Sponsor Jianhua Ma
Condition Sarcopenia
Study Type OBSERVATIONAL
Enrollment 1,220 participants
Start Date 2024-04-16
Primary Completion 2025-12-31

Eligibility & Interventions

Sex All sexes
Min Age 60 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
No Intervention: Observational Cohort

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 1,220 participants in total. It began in 2024-04-16 with a primary completion date of 2025-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Based on the analysis of dietary characteristics, gut microbiota diversity, and composition, this study investigates the relationships between the dietary inflammatory potential, gut microbiota, and sarcopenia. Furthermore, it explores the mediating role of gut microbiota in the association between the dietary inflammatory index and the risk of sarcopenia. The findings are expected to provide insights into the mechanisms through which dietary inflammation influences the development and progression of sarcopenia, and to offer a basis for dietary and nutritional interventions aimed at preventing or managing this condition.

Eligibility Criteria

Inclusion Criteria: * Permanent residents of the community aged 60 years or older. * Continuous residence duration in the community for more than 5 years. Exclusion Criteria: * Taking medications known to affect muscle function (e.g., corticosteroids, protein supplements, muscle enhancers). * Requiring walking assistance or having severe cognitive impairment that would preclude successful completion of assessments including bioelectrical impedance analysis (BIA), gait speed measurement, and handgrip strength testing. * Presence of a cardiac pacemaker, which contraindicates BIA measurement. * Diagnosis of one or more chronic diseases that significantly limit dietary intake.

Contact & Investigator

Central Contact

Jianhua Ma Doctor of Medicine

✉ majianhua@lzu.edu.cn

📞 0086 18993157029

Frequently Asked Questions

Who can join the NCT07211321 clinical trial?

This trial is open to participants of all sexes, aged 60 Years or older, studying Sarcopenia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07211321 currently recruiting?

Yes, NCT07211321 is actively recruiting participants. Contact the research team at majianhua@lzu.edu.cn for enrollment information.

Where is the NCT07211321 trial being conducted?

This trial is being conducted at Lanzhou, China.

Who is sponsoring the NCT07211321 clinical trial?

NCT07211321 is sponsored by Jianhua Ma. The trial plans to enroll 1,220 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology